BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
BD FACSLyric™ Flow Cytometer System with BD Multitest™ Assays Offers Reliability and Consistency Jul 19, 2017 FRANKLIN LAKES, N.J., July 19, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™... Read more